Physician profile
Robert Rubin
NPI 1497879555
$8,900.28
in general payments reported to CMS, 2019-2025
46 companies · $221 in 2025
The $221 reported for 2025 was more than what 78% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $1,614 · 2021: $1,612 · 2022: $1,640 · 2023: $1,411 · 2024: $600 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,231.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,229.34 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,030.57 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $866.01 | 2019-2024 | |
| Abbvie INC. | $748.07 | 2019-2023 | Qulipta, Linzess, Vraylar |
| Abbott Laboratories | $598.01 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $421.21 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $389.15 | 2019-2022 | |
| Lilly USA, LLC | $341.38 | 2019-2023 | Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $333.60 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.62 | 2019-2023 | Jardiance, Synjardy |
| Exact Sciences Corporation | $286.36 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $265.28 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $253.65 | 2019-2023 | Austedo Xr |
| Amarin Pharma, INC. | $250.21 | 2019-2022 | |
| Amgen INC. | $202.16 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.